 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholders Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in ...

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by ...

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript

Erytech Pharma reports Q1 results

ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript

Erytech Pharma reports 9M results

ERYTECH Pharma S.A. (ERYP) Q2 2022 Earnings Call Transcript

Erytech Pharma reports 1H results

Erytech Pharma Culls Work On Late-Stage Leukemia Asset, Evaluates Partnership Options

ERYTECH Pharma (ERYP) Investor Presentation - Slideshow

Phaxiam Therapeutics SA is a biopharmaceutical company, which develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. It operates through the following technical platforms: ERYCAPS, ERYCEV and ERYTECH. The ERYCAPS which uses a novel technology to encapsulate drug substances inside red blood cells. The ERYCEV focuses on potential of drug-loaded extracellular vesicles, derived from red blood cells. ERYTECH developing product candidates for patients with unmet medical needs. The company was founded in 2004 and is headquartered in Lyon, France.

Watchers	1,564
52-Wk Low	$3.00
52-Wk High	$14.00

Market Cap	$31.53M
Volume (M)	25,475.00
52-Wk High	$14.00
52-Wk Low	$3.00

ERYP ERYTECH Pharma S.A.

About

Feed

News

Fundamentals